# NIAAA Medications Development Clinical Investigations Network for the Treatment of Alcohol Use Disorder

> **NIH NIH N01** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $44,817

## Abstract

Medications development is a high priority program at National Institute on Alcohol Abuse and Alcoholism (NIAAA). Currently, only three medications are approved by the Food and Drug Administration (FDA) for the treatment of alcohol problems. These medications have demonstrated small to moderate effect sizes in clinical trials and do not work for everyone. 
Thus, the search for new molecular targets and more efficacious pharmacotherapies is critical.  The purpose of the current contract is to support clinical research sites as part of a medications development clinical trials network for phase II clinical trials for the treatment of alcohol use disorder.

## Key facts

- **NIH application ID:** 10591387
- **Project number:** 75N94021D00008-P00001-759402100001-1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** STEVEN SHOPTAW
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $44,817
- **Award type:** —
- **Project period:** 2021-03-25 → 2023-03-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10591387

## Citation

> US National Institutes of Health, RePORTER application 10591387, NIAAA Medications Development Clinical Investigations Network for the Treatment of Alcohol Use Disorder (75N94021D00008-P00001-759402100001-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10591387. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*